

(19) World Intellectual Property Organization
International Bureau



INTERNATIONAL PATENT COOPERATION TREATY (PCT)

(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/30879 A2

(51) International Patent Classification⁷: C07C 311/21,
C07D 317/58, 307/52, 213/65, 213/42, 209/88, A61K
31/44, 31/40, 31/36, 31/34, A61P 35/00, 17/06

(21) International Application Number: PCT/GB01/04326

(22) International Filing Date:
27 September 2001 (27.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0023986.3 29 September 2000 (29.09.2000) GB
60/297,784 14 June 2001 (14.06.2001) US
60/308,136 30 July 2001 (30.07.2001) US

(71) Applicant (for all designated States except US): PRO-
LIFIX LIMITED [GB/GB]; 91 Milton Park, Abingdon,
Oxfordshire OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WATKINS, Clare,
J. [GB/GB]; Prolifix Limited, 91 Milton Park, Abingdon,
Oxfordshire OX14 4RY (GB). ROMERO-MARTIN,
Maria-Rosario [ES/GB]; Prolifix Limited, 91 Milton
Park, Abingdon, Oxfordshire OX14 4RY (GB). MOORE,
Kathryn, G. [GB/GB]; Prolifix Limited, 91 Milton Park,
Abingdon, Oxfordshire OX14 4RY (GB). RITCHIE,
James [GB/GB]; Prolifix Limited, 91 Milton Park,
Abingdon, Oxfordshire OX14 4RY (GB). FINN, Paul, W.
[GB/GB]; Prolifix Limited, 91 Milton Park, Abingdon, Ox-
fordshire OX14 4RY (GB). KALVINSH, Ivars [LV/LV];
Latvian Institute of Organic Synthesis, Aizkraules Street
21, LV-1006 Riga (LV). LOZA, Einars [LV/LV]; Lat-
vian Institute of Organic Synthesis, Aizkraules Street
21, LV-1006 Riga (LV). DIKOVSKA, Klara [LV/LV];
Latvian Institute of Organic Synthesis, Aizkraules Street
21, LV-1006 Riga (LV). GAILITE, Vija [LV/LV]; Lat-
vian Institute of Organic Synthesis, Aizkraules Street

21, LV-1006 Riga (LV). VORONA, Maxim [LV/LV];
Latvian Institute of Organic Synthesis, Aizkraules Street
21, LV-1006 Riga (LV). PISKUNOVA, Irina [LV/LV];
Latvian Institute of Organic Synthesis, Aizkraules Street
21, LV-1006 Riga (LV). STARCHENKOV, Igor [—/LV];
Latvian Institute of Organic Synthesis, Aizkraules Street
21, LV-1006 Riga (LV). ADRIANOV, Victor [—/LV];
Latvian Institute of Organic Synthesis, Aizkraules Street
21, LV-1006 Riga (LV). HARRIS, C., John [GB/GB];
Biofocus plc, Sittingbourne Research Centre, Sitting-
bourne, Kent ME9 8AZ (GB). DUFFY, James, E., S.
[GB/GB]; BioFocus plc, Sittingbourne Research Centre,
Sittingbourne, Kent ME9 8AZ (GB).

(74) Agents: ARMITAGE, Ian, M. et al.; Mewburn Ellis, York
House, 23 Kingsway, London, Greater London WC2B 6HP
(GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS

(57) Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q¹ is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: -S(=O)₂NR¹- and -NR¹S(=O)₂-; R¹ is a sulfonamido substituent; and, Q² is an acid leader group; with the proviso that if J is -S(=O)₂NR¹-, then Q¹ is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both *in vitro* and *in vivo*, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.